UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 5, ~~2023 (January 4~~30, 2023)

DTRT HEALTH ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

Delaware	001-40774	86-3336784
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(IRS. EmployerIdentification No.)

1415 West 22^nd Street, Tower Floor

Oak Brook, IL 60523

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (312) 316-5473

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant	DTRTU	The Nasdaq Stock Market
Class A common stock, par value $0.0001 per share	DTRT	The Nasdaq Stock Market
Redeemable warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share	DTRTW	The Nasdaq Stock Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant	DTRTU	The Nasdaq Stock Market
Class A common stock, par value $0.0001 per share	DTRT	The Nasdaq Stock Market
Redeemable warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share	DTRTW	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.0201. ~~Termination~~Entry ofinto a Material Definitive Agreement.

AsThe ~~previously~~information ~~disclosed,~~under onItem ~~September 28, 2022, DTRT Health Acquisition Corp~~3.,01 aregarding ~~Delaware~~the ~~corporation~~Trust ~~(“DTRT”~~Agreement orAmendment ~~the~~is ~~“Company”),~~incorporated ~~entered~~ into anthis ~~agreement~~Item ~~and~~1.01 ~~plan of merger~~ by ~~and among DTRT, Grizzly New Pubco, Inc~~reference. (“New Pubco”), a wholly owned subsidiary of DTRT, Grizzly Merger Sub, Inc., a wholly owned subsidiary of New Pubco (“Grizzly Merger Sub”), Consumer Direct Holdings, Inc., a Montana corporation (“CDH”), and the Pre-Closing Holder Representative (as defined therein) (as it may be amended and/or restated from time to time, the “Merger Agreement”). The Merger Agreement would have provided, subject to its terms and conditions, for the initial business combination of DTRT (the “Business Combination”).

~~On January~~Item 4,3.01. ~~2023,~~Notice ~~the~~of ~~Company~~Delisting ~~received~~or aFailure ~~notice~~to ofSatisfy ~~termination~~a ofContinued ~~the~~Listing ~~Merger~~Rule or ~~Agreement~~Standard; ~~from~~Transfer ~~CDH~~of ~~(the “Notice”)~~Listing.

~~The~~On ~~Notice~~January 30, ~~terminates~~2023, stockholders of DTRT Health Acquisition Corp. (the ~~Merger~~“Company”) ~~Agreement~~approved asan ofamendment ~~January 11,~~(the ~~2023.~~“Charter ByAmendment”) ~~virtue~~to the Amended and Restated Certificate of Incorporation of the ~~termination~~Company of(the “Charter”) to (i) change the ~~Merger~~date ~~Agreement~~by which the Company must consummate a merger, ~~all~~share exchange, asset acquisition, stock purchase, reorganization or other ~~ancillary~~similar ~~agreements~~business ~~related~~combination towith ~~the~~one or more businesses or entities (an “Initial Business Combination”) ~~terminate~~from inMarch 7, ~~accordance~~2023 ~~with~~to ~~their~~the ~~terms.~~later of (A) AsJanuary a30, ~~result~~2023 ofand (B) the ~~termination~~date of effectiveness of the ~~Merger~~Charter ~~Agreement~~Amendment (the “Amended Termination Date”), (ii) change the date by which the Company’s ~~sponsor,~~must ~~DTRT~~consummate ~~Health~~an ~~Sponsor~~initial ~~LLC,~~business ~~has~~combination ~~informed~~or cease all operations except for the ~~Company~~purpose ~~that~~of itwinding ~~will~~up ~~not~~from ~~contribute~~18 ~~any~~months ~~additional~~from ~~funds~~the toclosing of the Company’s ~~trust~~initial ~~account.~~public ~~Accordingly,~~offering to the ~~Company~~Amended ~~will~~Termination ~~liquidate~~Date and ~~dissolve~~(iii) remove asthe ~~soon~~Redemption Limitation (as ~~practicable~~defined in ~~accordance~~the ~~with~~Charter) to allow the Company’s ~~charter~~to redeem shares of Class A common stock, par value $0.0001 per share (“Class A Common Stock”), notwithstanding the fact that such redemptions could result in the Company having net tangible assets of less than $5,000,001 after giving effect to such redemptions. The Company subsequently filed the Charter Amendment with the Secretary of State of the State of Delaware, which became effective upon filing.

~~SIGNATURE~~Additionally, the stockholders of the Company approved an amendment to the Investment Management Trust Agreement, dated September 1, 2021, by and between the Company and Continental Stock Transfer & Trust Company (“Continental”), as trustee (the “Trust Agreement Amendment”), to change the date on which Continental must commence liquidation of the Trust Account (as defined below) established in connection with the Company’s initial public offering (the “IPO”) to the Amended Termination Date (the “Trust Amendment Proposal”).

The stockholders further approved an adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there were insufficient votes for, or otherwise in connection with, the first and second proposal (the “Adjournment Proposal”).

Because the Company will not be able to complete an Initial Business Combination by the Amended Termination Date, the Company will (i) promptly, cease all operations, except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days after the Amended Termination Date, redeem the shares of Class A Common Stock (the “Redemption”) at a per-share price, payable in cash, equal to the aggregate amount on deposit in a trust account established for the benefit of the holders of Class A Common Stock (the “Trust Account”) as of the Amended Termination Date, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations (less up to an additional $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding shares of Class A Common Stock (the “Redemption Amount”), which redemption will completely extinguish the rights of the holders of Class A Common Stock as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law; and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the Board of Directors of the Company, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

On February 1, 2023, the Company (i) notified the Nasdaq Stock Market LLC ( “Nasdaq”) of the anticipated Redemption, liquidation and dissolution; and (ii) requested that Nasdaq (A) suspend trading of the Company’s shares of Class A Common Stock, redeemable warrants to purchase shares of Class A Common Stock and Units (collectively, the “Securities”) effective before the opening of trading on February 2, 2023, and (B) file with the Securities and Exchange Commission (the “SEC”) a Form 25 Notification of Removal from Listing and/or Registration (“Form 25”) to delist and deregister the Securities under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As a result, the Securities will no longer be listed on Nasdaq.

Following the filing of the Form 25, the Company intends to file a Form 15 Certification and Notice of Termination of Registration with the SEC, requesting that the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act be terminated with respect to the Securities.

Item 3.03. Material Modification to Rights of Security Holders.

The information under Item 3.01 regarding the Charter Amendment and the Redemption is incorporated into this Item 3.03 by reference.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

The information under Item 3.01 regarding the Charter Amendment is incorporated into this Item 5.03 by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Company’s special meeting of stockholders held on January 30, 2023, the stockholders of the Company considered and acted upon a proposal to approve the Charter Amendment (the “Charter Amendment Proposal”). The stockholders of the Company approved the Charter Amendment Proposal.

The following is a tabulation of the votes with respect to the Charter Amendment Proposal, which was approved by the Company’s stockholders:


For	Against	Abstain
8,035,335	0	0

The following is a tabulation of the votes with respect to the Trust Amendment Proposal, which was approved by the Company’s stockholders:


For	Against	Abstain
8,035,335	0	0

The following is a tabulation of the votes with respect to the Adjournment Proposal, which was approved by the Company’s stockholders:


For	Against	Abstain
8,018,234	17,101	0

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description of Exhibits

3.1		Certificate of Amendment to the Registrant’s Amended and Restated Certificate of Incorporation

104		Cover Page Interactive Data File-Embedded within the inline XBRL document.

Forward-Looking Statements

This Current Report on Form 8-K includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this press release, including, without limitation, regarding the early liquidation, de-listing of the Company’s Securities and Redemption Amount, are forward-looking statements. Words such as “expect” and “intend” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the publicly filed documents of the Company, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company’s securities filings can be accessed on the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


DTRT HEALTH ACQUISITION CORP.

By:		/s/ Mark Heaney
Name:		Mark Heaney
Title:		Chief Executive Officer and Executive Chairman

Date: February 3, 2023

DTRT HEALTH ACQUISITION CORP.

/s/ Mark Heaney

Name: Mark Heaney

Title: Chief Executive Officer and Executive Chairman

Dated: January 5, 2023

Filing Compare · DTRT Health Acquisition Corp.